Literature DB >> 20444884

Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner.

Guodong Li1, Ann M Thomas, Steven N Hart, Xiaobo Zhong, Dequan Wu, Grace L Guo.   

Abstract

As a unique nuclear receptor with only ligand-binding but no DNA-binding domain, small heterodimer partner (SHP) interacts with many transcription factors to inhibit their function. However, the regulation of SHP expression is not well understood. SHP is highly expressed in the liver, and previous studies have shown farnesoid X receptor (FXR) highly induces SHP by binding to a FXR response element (FXRRE) in the promoter of the Nr0b2 gene, which encodes SHP. The FXR-SHP pathway is critical in maintaining bile acid and fatty acid homeostasis. After genome-wide FXR binding by chromatin immunoprecipitation (ChIP) coupled to massively parallel sequencing (ChIP-seq), a novel FXRRE was found in the 3'-enhancer region of the Nr0b2 gene. This downstream inverted repeat separated by one nucleotide is highly conserved throughout mammalian species. We hypothesized that this downstream FXRRE is functional and may mediate a head-to-tail chromatin looping by interacting with the proximal promoter FRXRE to increase SHP transcription efficiency. In the current study, a ChIP-quantitative PCR assay revealed FXR strongly bound to this downstream FXRRE in mouse livers. The downstream FXRRE is important for FXR-mediated transcriptional activation revealed by luciferase gene transcription activation, as well as by deletion and site-directed mutagenesis. The chromatin conformation capture assay was used to detect chromatin looping, and the result confirmed the two FXRREs located in the Nr0b2 promoter and downstream enhancer interacted to form a head-to-tail chromatin loop. To date, the head-to-tail chromatin looping has not been reported in the liver. In conclusion, our results suggest a mechanism by which activation of FXR efficiently induces SHP transcription is through head-to-tail chromatin looping.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444884      PMCID: PMC2903909          DOI: 10.1210/me.2010-0014

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  37 in total

1.  The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp.

Authors:  L A Denson; E Sturm; W Echevarria; T L Zimmerman; M Makishima; D J Mangelsdorf; S J Karpen
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Quantitative analysis of chromosome conformation capture assays (3C-qPCR).

Authors:  Hélène Hagège; Petra Klous; Caroline Braem; Erik Splinter; Job Dekker; Guy Cathala; Wouter de Laat; Thierry Forné
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

3.  Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis.

Authors:  Ronni Nielsen; Thomas Askov Pedersen; Dik Hagenbeek; Panagiotis Moulos; Rasmus Siersbaek; Eva Megens; Sergei Denissov; Michael Børgesen; Kees-Jan Francoijs; Susanne Mandrup; Hendrik G Stunnenberg
Journal:  Genes Dev       Date:  2008-11-01       Impact factor: 11.361

4.  Long-range interactions between three transcriptional enhancers, active Vkappa gene promoters, and a 3' boundary sequence spanning 46 kilobases.

Authors:  Zhe Liu; William T Garrard
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

5.  Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

Authors:  C J Sinal; M Tohkin; M Miyata; J M Ward; G Lambert; F J Gonzalez
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

6.  Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner.

Authors:  KehDih Lai; Douglas C Harnish; Mark J Evans
Journal:  J Biol Chem       Date:  2003-07-02       Impact factor: 5.157

7.  Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine.

Authors:  Ann M Thomas; Steven N Hart; Bo Kong; Jianwen Fang; Xiao-Bo Zhong; Grace L Guo
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

8.  De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis.

Authors:  Mohamed Sabry Hamza; Sebastian Pott; Vinsensius B Vega; Jane S Thomsen; Gopalan Srinivasan Kandhadayar; Patrick Wei Pern Ng; Kuo Ping Chiu; Sven Pettersson; Chia Lin Wei; Yijun Ruan; Edison T Liu
Journal:  PLoS One       Date:  2009-03-20       Impact factor: 3.240

9.  Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data.

Authors:  Anton Valouev; David S Johnson; Andreas Sundquist; Catherine Medina; Elizabeth Anton; Serafim Batzoglou; Richard M Myers; Arend Sidow
Journal:  Nat Methods       Date:  2008-09       Impact factor: 28.547

10.  Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data.

Authors:  Raja Jothi; Suresh Cuddapah; Artem Barski; Kairong Cui; Keji Zhao
Journal:  Nucleic Acids Res       Date:  2008-08-06       Impact factor: 16.971

View more
  23 in total

Review 1.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis.

Authors:  Sayeepriyadarshini Anakk; Mitsuhiro Watanabe; Scott A Ochsner; Neil J McKenna; Milton J Finegold; David D Moore
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

3.  Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.

Authors:  Xian Pan; Yoon-Kwang Lee; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2015-04-29       Impact factor: 3.922

4.  Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.

Authors:  Yong Yan; Yanhua Sha; Xianzhang Huang; Wei Yuan; Fan Wu; Jinsong Hong; Shaomei Fang; Bo Huang; Cheng Hu; Bailin Wang; Xueli Zhang
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

Review 5.  Tissue-specific function of farnesoid X receptor in liver and intestine.

Authors:  Yan Zhu; Fei Li; Grace L Guo
Journal:  Pharmacol Res       Date:  2011-01-04       Impact factor: 7.658

6.  Phosphorylation of Farnesoid X Receptor at Serine 154 Links Ligand Activation With Degradation.

Authors:  Takuyu Hashiguchi; Shingo Arakawa; Shogo Takahashi; Frank J Gonzalez; Tatsuya Sueyoshi; Masahiko Negishi
Journal:  Mol Endocrinol       Date:  2016-08-29

7.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

8.  Pregnancy represses induction of efflux transporters in livers of type I diabetic mice.

Authors:  Lauren M Aleksunes; Jialin Xu; Eugenia Lin; Xia Wen; Michael J Goedken; Angela L Slitt
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

9.  Role of nuclear receptors in lipid dysfunction and obesity-related diseases.

Authors:  Hollie I Swanson; Taira Wada; Wen Xie; Barbara Renga; Angela Zampella; Eleonora Distrutti; Stefano Fiorucci; Bo Kong; Ann M Thomas; Grace L Guo; Ramesh Narayanan; Muralimohan Yepuru; James T Dalton; John Y L Chiang
Journal:  Drug Metab Dispos       Date:  2012-10-04       Impact factor: 3.922

10.  Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.

Authors:  Guodong Li; Bo Kong; Yan Zhu; Le Zhan; Jessica A Williams; Ossama Tawfik; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2013-06-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.